KUMJ | VOL. 22 | NO. 1 | ISSUE 85 | JANUARY - MARCH
Thrombolysis with Tenecteplase for Basilar Artery Occlusion in Neuro and Allied Clinic: Importance of Clinical Assessment and Drip and Ship Model in Nepal
Thapa L, Ghimire MR, Bhattarai S, Shrestha AM, Rai N, Paudel R
Abstract: Tenecteplase, a new thrombolytic drug, is now widely recommended and used for
treating acute ischemic stroke, and timely thrombolysis within 4.5 hours is crucial
for better outcomes. However, due to limited stroke awareness, transportation
difficulties, and inadequate access to experts and comprehensive stroke care
centers, fewer than 15% of stroke patients in Nepal receive thrombolytic therapy.
The “drip and ship” model, which involves starting thrombolysis at a noncomprehensive
stroke
care
center
and
transferring
the
patient
to
another
center
for
further care, can effectively overcome these obstacles, provided trained personnel
are available at non-comprehensive stroke care centers. We report a case of acute
ischemic stroke treated with thrombolysis within 4.5 hours of symptom onset at a
non-comprehensive stroke care center, followed by transfer to another center for
ongoing care, demonstrating the feasibility and potential benefits of the drip and
ship model in resource-limited settings.
Keyword : Basilar artery occlusion, Drip and ship model, Tenecteplase, Thrombolysis
